Home › Regulus Therapeutics Inc (RGLS) Earns Buy Rating from Analysts at Chardan Capital
 

Keywords :   


Regulus Therapeutics Inc (RGLS) Earns Buy Rating from Analysts at Chardan Capital

2016-04-14 08:07:13| Biotech - Topix.net

The brokerage set a "buy" rating and a $15.00 price target on the biopharmaceutical company's stock. Chardan Capital's target price suggests a potential upside of 91.08% from the company's previous close.

Tags: buy rating capital analysts

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.11 onecontrol Chamaeleo Tail Loop MKII
16.11ZIGGY ORDER-MADE
16.116
16.11SwitchCoLotta
16.11 p8
16.11mtg foil 3
16.11RolandSP-404SX
16.11DVD 42
More »